This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. A distinct feature of SPAC 3.0
The world of banking can be broadly divided into: Retail Banks: Think of your local branch where you have your checking and savings accounts. You deposit $10,000 in a bank savings account earning 0.5% Overdraft Fees: If you've ever spent more than what's in your checking account, you've probably been hit with an overdraft fee.
According to Nasdaq , in 2015, SPACs made up approximately 12% of the IPO market, but by 2020, that number had risen to approximately 53%. SPACs are predicted to be an even higher percentage of the 2021 market share, with SPACs representing 79% of the January IPOs. In In re Benjamin H.
There are compelling rationales for adopting a dual-class structure, but even proponents of the structure generally acknowledge that these benefits are significantly mitigated once the dual-class shares are out of the hands of the founders and/or pre-IPO stockholders. Potential carve outs for M&A voting agreements. Stockholder litigation.
AFME notes that similar themes are being addressed in ongoing discussions by other policymakers, and it is important for the respective UK initiatives to take account of developments in other jurisdictions such as the US and EU.”
As SPAC IPOs broke records – in both value and volume – in 2020 (and again in 2021), it was inevitable that stockholder litigation would follow. Churchill was incorporated in Delaware in October 2019 and closed its $1.1 billion IPO in February 2020. On January 3, in In re MultiPlan Corp. Stockholders Litigation (Del.
Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8
Although global deal value was a subdued $966 billion in the first half of 2020 (down nearly 50% compared to the first half of 2019), momentum skyrocketed in the second half of the year to nearly $2.2 compared to 2019. compared to 2019, and up even higher (57%) when looking solely at US deal value. COVID-19: The New Normal.
The MLB started allowing PE ownership in 2019, and the NHL followed suit in 2021. Exits seem dependent on finding another PE firm or consortium willing to pay more, and options like IPOs and acquisitions by “strategics” (normal companies) are less viable due to league rules on ownership.
If 2019 was the year of life sciences mega-deals, 2020 was the year of COVID-19, as the global pandemic permeated every aspect of the dealmaking landscape, with the life sciences sector being no exception. billion deal inked in 2019 that included more than $2 billion in contingent payments based on the achievement of certain milestones.
Private equity’s increased interest in life sciences , with PE buyers accounting for 47% of deal volume in the first half of 2021 , compared to a long?term on transactions over 2019’s mega?mergers. But deal value – which totaled $108 billion as of December 15, 2021 – was slightly down from 2020 and significantly down from 2019.
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content